🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

CTT, LLC and NEU: Three ASX Shares Start the Week on a High

Published 28/05/2024, 02:15 am
© Reuters.  CTT, LLC and NEU: Three ASX Shares Start the Week on a High
AXJO
-
LLESY
-

The S&P/ASX 200 Index is off to a robust start this week. The benchmark index closed 0.79% up at 7,788.30 points. Several ASX shares are outperforming the market, posting significant gains. Here are three standout performers and the reasons behind their upward momentum:

Cettire Ltd (ASX: CTT) soars over 11%

Cettire Ltd's share price has surged 11.34% to AU$2.65 apiece. Investors have flocked to this online luxury products retailer after the company firmly denied allegations of selling fake products. Cettire stated, "Since our commercial launch in 2017, we have processed over 2 million individual orders without a single confirmed case of a non-genuine item being sold on our platform." Management also pointed out that negative media coverage has been driven by parties with short positions in Cettire shares, aiming to profit from a temporary decline in the share price.

Lendlease Group (ASX: LLC) Climbs 8%

Lendlease Group's share price has increased by 8.23% to AU$6.38 apiece following the release of a significant strategy update. The property developer announced plans to simplify its global business and control costs. Lendlease will exit its struggling international construction projects and focus on its integrated Australian real estate business, along with its international investment management capabilities. These strategic moves are expected to free up AU$4.5 billion of capital from its offshore development projects and assets.

Neuren Pharmaceuticals Ltd (ASX: NEU) Jumps 15%

Neuren Pharmaceuticals Ltd's share price has jumped 15.64% to AU$23.95 apiece, driven by positive trial results. The company's phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS) showed a "statistically significant improvement" across all four efficacy measures. Neuren CEO Jon Pilcher commented, "We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet needs, and we can now continue towards our goal of developing the first approved treatment."

Other ASX Shares Making Waves

While these companies are the top performers today, the overall market is seeing positive movements across various sectors. The strong performance of the S&P/ASX 200 Index reflects investor optimism and a favorable economic outlook. Market analysts suggest that this trend could continue if macroeconomic conditions remain stable and corporate earnings meet or exceed expectations.

Read more on Kalkine Media

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.